ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2026
Interstitial lung disease in psoriasis: A systematic review and meta-analysis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPsoriatic disease is associated with several extra-cutaneous complications, including cardiovascular disease and type 2 diabetes. Whether psoriatic disease is associated with interstitial lung disease (ILD) remains uncertain. The aim of this study was toquantify the prevalence of ILD overall and across specific subtypes of psoriatic disease.
methodsWe systematically searched PubMed, Embase, and Scopus for original studies reporting the prevalence of ILD in adults with psoriatic disease. Pooled prevalence estimates were calculated using proportional random-effects meta-analysis, with subgroup analyses stratified by factors including psoriatic disease type, sex, and smoking history. Random-effects meta-regression was conducted to examine the influence of age and disease duration.
resultsOf 863 records screened, 11 studies were included. The pooled ILD prevalence in any psoriatic disease was 3.6% (95% CI: 2.1-5.0%). Meta-regression indicated that ILD prevalence increased by 0.19 percentage points per year (95% CI: 0.16-0.22) from approximately 38 years of age. Subgroup analysis showed ILD prevalences of 2.4% (95% CI: 1.1-3.6%) in psoriasis vulgaris, 5.7% (95% CI: 2.5-8.9%) in psoriatic arthritis, and 8.4% (95% CI: 6.4-10.4%) in generalized pustular psoriasis (GPP). ILD prevalence was 1.2% (95% CI: 0.1-2.2%) in never-smokers versus 6.7% (95% CI: 2.3-11.1%) in ever-smokers.
conclusionsILD may represent a clinically relevant comorbidity in patients with psoriatic disease, particularly psoriatic arthritis and GPP. This increased prevalence may reflect chronic systemic inflammation and exposures such as medications and cigarette smoke. Further research is needed to elucidate the underlying mechanisms and to assess whether early detection and targeted interventions can improve outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.